Prestige Consumer Healthcare (NYSE:PBH) Announces Earnings Results, Beats Estimates By $0.04 EPS

Prestige Consumer Healthcare (NYSE:PBH) announced its quarterly earnings results on Thursday. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.86 by $0.04, Briefing.com reports. The company had revenue of $267.10 million for the quarter, compared to analysts’ expectations of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.60% and a return on equity of 13.48%. Prestige Consumer Healthcare’s revenue was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.06 EPS. Prestige Consumer Healthcare updated its FY25 guidance to $4.40-4.46 EPS and its FY 2025 guidance to 4.400-4.460 EPS.

Prestige Consumer Healthcare Stock Performance

PBH traded down $0.59 during midday trading on Friday, hitting $66.25. 274,252 shares of the company traded hands, compared to its average volume of 250,556. The company has a quick ratio of 2.02, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $3.29 billion, a PE ratio of 15.89, a price-to-earnings-growth ratio of 2.00 and a beta of 0.49. The company’s 50-day moving average is $68.16 and its 200 day moving average is $68.48. Prestige Consumer Healthcare has a 52 week low of $56.34 and a 52 week high of $75.31.

Wall Street Analyst Weigh In

PBH has been the topic of a number of analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $80.00 price target on shares of Prestige Consumer Healthcare in a research note on Tuesday, May 21st. StockNews.com cut shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 21st. Finally, DA Davidson restated a “buy” rating and set a $93.00 target price on shares of Prestige Consumer Healthcare in a research note on Friday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.25.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.